BioNTech
BioNTech SE, short for Biopharmaceutical New Technologies, is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
| BioNTech SE | |
|---|---|
| Type | Public |
| Traded as | Nasdaq: BNTX |
| Industry | Biotechnology, pharmaceuticals |
| Founded | 2008, Mainz, Germany |
| Founder | Uğur Şahin, Özlem Türeci, Christoph Huber |
| Headquarters | Mainz, Germany |
| Area served | Worldwide |
| Key people | Uğur Şahin (CEO), Özlem Türeci (chief medical officer) |
| Products | Comirnaty COVID-19 vaccine, mRNA cancer immunotherapies |
| Services | mRNA therapeutics, cell therapies, antibody development |
| Website | biontech.com |
The company works through technology platforms including messenger RNA therapies, targeted therapies and immunomodulators. Its pipeline includes several late-stage oncology programmes testing combination approaches. In infectious disease, BioNTech developed Comirnaty in partnership with Pfizer, the first approved mRNA vaccine, used widely during the COVID-19 pandemic.
BioNTech is an unusual case in modern pharmaceuticals: a company founded to pursue individualised cancer therapy that, within twelve years and under extraordinary time pressure, applied the same platform to produce one of the most widely administered medical products in history.
History
Foundation, 2008 to 2014
BioNTech was founded in 2008 on research by Uğur Şahin, Özlem Türeci and Christoph Huber, with seed investment of 180 million euros from MIG Capital, a Munich venture capital firm, the family office of Andreas and Thomas Strüngmann, and Helmut Jeggle, later chairman of the supervisory board. It acquired EUFETS and JPT Peptide Technologies in 2009.
The company's origins lie in work by Şahin, Türeci and their teams over several decades on the use of messenger RNA as a therapeutic. Their aim was individualised cancer immunotherapy: sequencing a patient's tumour, identifying the mutations specific to it, and manufacturing an RNA product instructing the immune system to recognise them.
Three technical obstacles stood in the way. Messenger RNA is unstable in the body, it is difficult to deliver into target cells, and the resulting protein production was initially low and short-lived. The company's work addressed each, developing stabilised constructs and lipid nanoparticle formulations for delivery.
In 2013 the Hungarian biochemist Katalin Karikó, who later shared the 2023 Nobel Prize in Physiology or Medicine, joined BioNTech as a senior vice president, remaining afterwards as an external adviser. Karikó had discovered that modifying the nucleoside uridine reduced the immunogenicity of messenger RNA, making it suitable for therapeutic use. Her work, long overlooked and difficult to fund, underpinned the platform.
Expansion and listing, 2015 to 2019
Research on mRNA mechanisms was published between 2014 and 2018, and commercial collaborations with companies and scientific institutions began in 2015. In January 2018 BioNTech closed a 270 million dollar Series A financing to expand its immunotherapy research.
In August 2018 it entered a multi-year research and development collaboration with Pfizer to develop mRNA-based influenza vaccines, under which Pfizer would take sole responsibility for clinical development and commercialisation after BioNTech completed a first-in-human study. This existing relationship proved decisive two years later.
In July 2019 Fidelity Management and Research led a 325 million dollar Series B round with participation from Redmile Group, Invus, Mirae Asset Financial Group, Platinum Asset Management, Jebsen Capital, Steam Athena Capital, BVCF Management and the Strüngmann family office. In September 2019 the Bill & Melinda Gates Foundation contributed 55 million dollars, and in December the European Investment Bank provided a 50 million euro loan under the European Commission's Investment Plan for Europe.
BioNTech listed American depositary shares on the Nasdaq Global Select Market on 10 October 2019, raising gross proceeds of 150 million dollars.
COVID-19, from 2020
BioNTech launched Project Lightspeed in January 2020, days after the SARS-CoV-2 genetic sequence was first published, to develop an mRNA vaccine. The speed was possible because an mRNA vaccine requires only the sequence of the target protein, not the virus itself, so design could begin as soon as the sequence was available.
In March 2020 the company partnered with Fosun Pharma for mainland China, Hong Kong and Macau and with Pfizer for the rest of the world, excluding Germany and Turkey where BioNTech retained rights. Clinical trials began in April 2020 across several regions.
Funding followed quickly: a 100 million euro loan from the European Investment Bank in June 2020, a 375 million euro grant from the German Federal Ministry of Education and Research, 250 million euros from Temasek Holdings through ordinary shares and convertible notes, and further private placements of convertible bonds.
The vaccine, Comirnaty, received its first emergency authorisation in the United Kingdom in December 2020 and subsequently in the United States, European Union and elsewhere. Billions of doses were administered worldwide, and BioNTech moved from a loss-making research company to one of the most profitable businesses in Germany within a single year, with the resulting tax receipts materially affecting the public finances of the city of Mainz.
The company has since directed its resources back toward oncology, its founding purpose, including individualised neoantigen therapies in trials for colorectal and pancreatic cancer, and has acquired antibody and cell therapy capabilities, including a substantial expansion into China-originated oncology assets.
Controversies
Vaccine patent disputes
BioNTech and Pfizer have been defendants and claimants in extensive litigation over mRNA vaccine patents. Moderna sued both companies in 2022 alleging infringement of patents covering modified nucleosides and lipid nanoparticle delivery. CureVac brought proceedings in Germany and the United Kingdom, where courts reached differing conclusions on validity and infringement. The United States National Institutes of Health and the University of Pennsylvania have also been involved in claims relating to foundational work. BioNTech has argued that its technology was developed independently over more than a decade.
Vaccine equity
Comirnaty was distributed overwhelmingly to high-income countries during the first year of availability, and BioNTech and Pfizer were criticised by the World Health Organization, by the governments of several developing countries and by campaign organisations for declining to support a waiver of intellectual property rights under the TRIPS agreement and for not licensing production more widely.
BioNTech's response was that manufacturing mRNA vaccines requires specialised capability that cannot be transferred quickly by waiving patents, and it established a programme to build modular production facilities, the first of which was delivered to Rwanda. Critics, including Médecins Sans Frontières, argued that the initiative was slower and smaller than a licensing approach would have been and that it preserved the company's control over the technology.
Pricing
The price of Comirnaty rose substantially after the initial pandemic supply agreements expired, drawing criticism in the United States and Europe given the scale of public funding that supported its development, including the 375 million euro German grant and European Investment Bank lending. The companies argue that commercial pricing reflects the shift from government procurement of a pandemic product to a routine seasonal market.
Cancer vaccine expectations
Public statements by the founders about the prospects for mRNA cancer vaccines have at times attracted criticism from oncologists for raising expectations ahead of the evidence, particularly forecasts of availability within specific timeframes. The company's late-stage oncology programmes remain in trials, and individualised therapy presents manufacturing and regulatory challenges quite different from those of a single standard vaccine.
Concentration risk
BioNTech's revenue remains heavily dependent on a single product whose market has contracted sharply since the pandemic, and analysts have questioned whether the company can convert its accumulated capital into a durable oncology business before that revenue declines further. The company holds a very large cash position accumulated during the pandemic, which it has been deploying into acquisitions and trials.
See also
References